Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung CancerAlice T. Shaw, Pasi A. Jänne, Keith D. Wilner et al.|New England Journal of Medicine|2013Cited by 3.4k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> MutationsLecia V. Sequist, Martin Schüler, James Chih‐Hsin Yang et al.|Journal of Clinical Oncology|2013Cited by 3.2k
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trialsJames Chih‐Hsin Yang, Lecia V. Sequist, Yi‐Long Wu et al.|The Lancet Oncology|2015Cited by 1.6k
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiLMartin Reck, Christian Manegold, Joachim von Pawel et al.|Journal of Clinical Oncology|2009Cited by 1.5k
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple MyelomaDavid H. Henry, Howard Yeh, Luís Costa et al.|Journal of Clinical Oncology|2011Cited by 1.3k